| 01:00p | European Bourses Hammered by Recession Fears; Euro Falls to 20-Year Low | MT |
| 11:46a | GLOBAL MARKETS LIVE : J Sainsbury, Foxconn, JPMorgan, Comcast, Tesla... | |
| 09:51a | ASTRAZENECA : Buy rating from Deutsche Bank | MD |
| 09:37a | AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening ha.. | AQ |
| 06:23a | ASTRAZENECA : to acquire TeneoTwo and its clinical-stage T-cell engager, strengthening hae.. | PU |
| 06:20a | MARKETSCREENER'S WORLD PRESS REVIEW : July 5, 2022 | |
| 06:06a | AstraZeneca to Acquire Cancer Drug Maker TeneoTwo | MT |
| 05:55a | PETER THIEL : Stock Futures Head Lower as Recession Fears Loom Large | DJ |
| 03:43a | AstraZeneca Moves to Boost Blood Cancer Pipeline Via $1.3 Billion TeneoTwo Acquisition | MT |
| 03:30a | AstraZeneca to Buy TeneoTwo in Up to $1.27 Billion Deal | MT |
| 02:24a | AstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion | RE |
| 02:23a | AstraZeneca To Buy TeneoTwo in Up tp $1.27 Billion Deal | MT |
| 12:31a | AstraZeneca to Buy TeneoTwo for Up to $1.27 Billion | DJ |
| 07/01 | SECTOR UPDATE : Health Care Stocks Rebound Late | MT |
| 07/01 | SECTOR UPDATE : Health Care Stocks Struggling for Direction | MT |
| 07/01 | AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials | MT |
| 07/01 | AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination.. | BU |
| 07/01 | AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® Combinations in Patients.. | CI |
| 07/01 | AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica | MT |
| 07/01 | New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten .. | AQ |
| 07/01 | Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN.. | AQ |
| 07/01 | Pharmaceutical companies still have the upper hand | |
| 07/01 | Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility | DJ |
| 07/01 | Oxford Biomedica signs new deal to make AstraZeneca COVID shot | RE |
| 07/01 | Oxford Biomedica, AstraZeneca Unit Ink Three-year Deal To Manufacture COVID-19 Vaccines | MT |
| 07/01 | Oxford Biomedica signs new deal to make AstraZeneca COVID shot | RE |
| 06/30 | COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna.. | RE |
| 06/30 | IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Resp.. | BU |
| 06/30 | AstraZeneca Says Phase 3 Trial Interim Data Show Imfinzi Plus Chemotherapy Improves Pat.. | MT |
| 06/30 | ASTRAZENECA : Imfinzi plus chemotherapy significantly improved pathologic complete respons.. | PU |
| 06/30 | Astrazeneca's Imfinzi Plus Chemotherapy Significantly Improves Pathologic Complete Resp.. | CI |
| 06/30 | S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people | RE |
| 06/30 | AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial | RE |
| 06/30 | AstraZeneca's Late-stage Lung Cancer Drug Trial Shows Improved Pathologic Complete Resp.. | MT |
| 06/30 | AstraZeneca Announces Positive High-Level Results from A Planned Interim Analysis of th.. | CI |
| 06/30 | AstraZeneca Says Imfinzi Improved Pathologic Complete Response in Lung Cancer | DJ |
| 06/29 | European ADRs Move Slightly Higher in Wednesday Trading | MT |
| 06/29 | FTSE 100 Closes Down 0.2% as Uncertainty Persists | DJ |
| 06/29 | FTSE 100 retreats from two-week high on slowdown worries | RE |
| 06/29 | Taiwan to receive first doses of Novavax COVID vaccine this week | RE |
| 06/29 | SK Bioscience Shares Advance on Covid-19 Vaccine Approval | DJ |
| 06/28 | AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as A.. | AQ |
| 06/28 | Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e.. | AQ |
| 06/28 | Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e.. | AQ |
| 06/27 | European Union Recommends Approval for AstraZeneca and Daiichi Sankyo's Enhertu | CI |
| 06/27 | Merck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatm.. | MT |
| 06/27 | Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive meta.. | AQ |
| 06/27 | AstraZeneca Pharma India Sets Record Date for Fiscal 2022 Final Dividend | MT |
| 06/27 | AstraZeneca Partner Daiichi Sankyo Says EMA's Committee Backs Approval of Trastuzumab D.. | MT |
| 06/27 | AstraZeneca's Lynparza, Enhertu Win EU Panel's Backing for Approval in Breast Cancer | MT |
| 06/27 | AstraZeneca PLC Announces Lynparzar Ecommended for Approval in the EU by CHMP as Adjuva.. | CI |
| 06/27 | Trastuzumab Deruxtecan Recommends for Approval in the EU by CHMP for Patients with HER2.. | CI |
| 06/27 | AstraZeneca-Daiichi Sankyo Enhertu Breast Cancer Drug Is Recommended for EU Approval | DJ |
| 06/27 | AstraZeneca Lynparza Breast Cancer Treatment Is Recommended for EU Approval | DJ |
| 06/24 | AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indicati.. | MT |
| 06/24 | Sanofi, GSK variant-specific COVID shot found effective against Omicron | RE |
| 06/23 | AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu | MT |
| 06/23 | EU watchdog backs Valneva's COVID shot as contract talks go on | RE |
| 06/23 | AstraZeneca Drug Candidate to Treat Wilson Disease Meets Primary Endpoint in Phase 3 Tr.. | MT |
| 06/23 | AstraZeneca's Investigational Drug Meets Primary Endpoint for Wilson Disease | MT |
| 06/23 | ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Pot.. | BU |
| 06/23 | ASTRAZENECA : ALXN1840 shows rapid and sustained improvement in copper mobilisation from t.. | PU |
| 06/22 | ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively | DJ |
| 06/22 | European Medicines Agency Validates AstraZeneca-Daiichi Sankyo Application for Breast C.. | MT |
| 06/22 | AstraZeneca and Merck - Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus A.. | AQ |
| 06/22 | PROpel Phase III trial positive results of LYNPARZA (olaparib) plus abiraterone in 1st-.. | AQ |
| 06/22 | Improved outcome for prostate cancer patients in Phase III PROpel trial | AQ |
| 06/22 | AstraZeneca Partner Daiichi Sankyo Says Type II Variation Application for Breast Cancer.. | MT |
| 06/22 | COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown | RE |
| 06/22 | Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag.. | MT |
| 06/22 | Biocartis Group NV Announces New Agreement with AstraZeneca for the Development and Mar.. | CI |
| 06/21 | AstraZeneca-Merck & Co.'s Lynparza Delays Prostate Cancer Progression In Late-stage Stu.. | MT |
| 06/21 | Merck, AstraZeneca Publish Phase 3 Data for Lynparza-Abiraterone Combo to Treat Prostat.. | MT |
| 06/21 | European Bourses Close in Green for Second Consecutive Day | MT |
| 06/21 | Ionis Pharmaceuticals, AstraZeneca's Eplontersen Meets Primary, Secondary Endpoints in .. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
